Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,046

Document Document Title
WO/2022/160737A1
The present invention relates to a crystal form of a tetrahydropyran ring compound and a preparation method therefor. Specifically disclosed are the polymorphism of the compound represented by formula (I), and a preparation method for th...  
WO/2022/157233A1
The present invention relates to compounds of the following formula (I): as well as their preparation process; their use in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin pr...  
WO/2022/135173A1
Provided is an Escherichia coli strain, H03A2190830. The deposit number thereof is CCTCC NO: M2019900. Further provided are a method for producing a polysialic acid by means of using the Escherichia coli, and a method for producing a sia...  
WO/2022/124859A1
The present invention relates to a 1'-homoadenosne derivative, and a pharmaceutical composition for preventing or treating hypoadiponectinemia-associated diseases or psoriasis, containing same as an active ingredient, and provides: a 1'-...  
WO/2022/119541A1
The present invention relates to a film coated tablet formulation comprising dapagliflozin and metformin hydrochloride wherein dapagliflozine has a d (0.9) particle size between 20 µm to 140 µm. Further, the present invention also rela...  
WO/2022/078974A1
The present disclosure relates generally to malonyl steviol glycosides and the use of such compounds for various comestible uses, such as sweetening a flavored product or enhancing the sweetness of another sweetener. In some aspects, the...  
WO/2022/067724A1
Provided are an SGLT-2 inhibitor sarcosine co-crystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said co-crystal has higher safety and lower costs; a drug co-crystal has higher stability, and during the ...  
WO/2021/233314A1
Provided is a method for economically and efficiently preparing β-D-(1,4)-mannuronate oligosaccharide as represented by formula (IX). Particularly, the method comprises: using economical and easily available 1,2,3,4,6-penta-O-acetyl-D-m...  
WO/2021/197363A1
The present invention relates to a 2-alkynyl mannose derivative and an application thereof. The mannose derivative, as well as a pharmaceutically acceptable salt, an isotope and an isomer thereof have the structure represented by general...  
WO/2021/183750A2
The present disclosure generally describes methods of preparing l'-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (Il-a) in a flow reactor.  
WO/2021/175296A1
The present invention provides an intermediate of Remdesivir and a preparation method therefor. The preparation method has the advantages of low costs, high yield, good product purity, etc. , and can achieve the efficient synthesis of Re...  
WO/2021/168004A1
The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.  
WO/2021/105779A1
The present invention relates to solid compounds also referred to as new solid forms (NSF) of Dapagliflozin (DPG) co-crystals and co-amorphs, wherein the co-former is selected from: a) a carboxylic acid derivative having an amino group i...  
WO/2021/073064A1
A method for improving the yield rate of an Amadori rearrangement product (ARP) on the basis of a mechanism of inhibiting degradation of the ARP by an adduct of a tea polyphenol and deoxyosone. The specific method comprises: dissolving a...  
WO/2021/054474A1
In the present invention, a disaccharide unit for synthesizing a useful sugar chain for suppressing the development of dystroglycanopathy is obtained and used to reconstitute a post-phosphoryl sugar chain. Provided are: a disaccharide ...  
WO/2021/055753A1
Methods for inhibiting CMP-sialic acid synthetases and other CMP-sugar synthetases using sugar derivatives such as dehydro-sugars and anhydro-sugars are described, as well as methods for treating conditions including bacterial infections...  
WO/2021/018044A1
Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically inv...  
WO/2021/019509A1
The present document relates to a process for the preparation of the crystalline form II of sotagliflozin from compound of formula (A), said process being continuously performed and comprising at least the steps of: a) performing in a re...  
WO/2021/019507A1
The present document relates to a process for the preparation of the crystallineform II of sotagliflozin, wherein said crystalline form II of sotagliflozin is directly obtained from the following compound of formula (A) and by using tolu...  
WO/2021/004498A1
It relates to glucopyranosyl derivative of formula (I) as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, a pharmaceutically acceptable salt, or a stereoisomer thereof, and further relates to a pharmaceutical composition cont...  
WO/2020/242253A1
The present invention relates to a novel empagliflozin derivative, which is a novel compound that is useful as an SGLT-2 inhibitor. In addition, a novel empagliflozin derivative according to the present invention exhibits a relatively hi...  
WO/2020/211668A1
Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.  
WO/2020/204691A1
The present invention discloses a functionalized glycolipid having a formula (I): (I) where Y is selected from a group consisting of O, NH and NAc; wherein A is selected from a group of bi-antennary hydrophobic domain having a formula (I...  
WO/2020/129901A1
[Problem] To provide a novel method for preparing a ketone compound. [Solution] Provided is a method for preparing compound (I) represented by formula (I), the method comprising a step for obtaining compound (I) by reacting compound (II)...  
WO/2020/083871A1
The present invention relates to novel oligogalacturonans having a degree of methylation of 0 and a degree of polymerisation of 1 to 10, and to the use thereof for stimulating defence responses of plants against pathogenic microorganisms.  
WO/2020/061129A1
Disclosed herein are compositions and methods for labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents to a variety of cell types...  
WO/2020/040433A1
The present invention relates to a method for preparation of a dapagliflozin precursor, which is a SGLT-2 inhibitor and, particularly, to a method for preparation of the dapagliflozin precursor, which is the compound of chemical formula ...  
WO/2020/036382A1
The present invention relates to a method for producing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as a SGLT inhibitor. A method for synthesizing a compound of formula 7 according to the pre...  
WO/2020/002076A1
The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or...  
WO/2020/001812A1
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.  
WO/2020/002054A1
The present invention relates to a process for the cosmetic treatment of keratin materials, comprising the application to said materials, such as the skin, of a composition comprising a compound (I) The invention relates in particular to...  
WO/2019/151128A1
A cell labeling agent according to the present invention includes a monosaccharide derivative having a six-membered ring structure metabolized by sialic acid in a sialic acid biosynthesis pathway of a cell. Among groups bonded to carbon ...  
WO/2019/115616A1
The present invention relates to Novel 1,7-dicarba-closo- dodecaborane(12) (meta-carbaborane)-derived carboxylic acids suitable for peptide modification for application in boron neutron capture therapy (BNCT).  
WO/2019/115617A1
The present invention relates to Novel 1,7-dicarba-closo-dodecaborane (meta-carbaborane)-derived carboxylic acids and amines according to Formula (I) suitable for peptide modification for application in boron neutron capture therapy (BNC...  
WO/2019/106122A1
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.  
WO/2019/043069A1
The present invention relates to a new class of sucrose esters and a method for their preparation.  
WO/2018/207111A1
The present invention relates to an industrially feasible and economically viable process for preparation of SGLT2 inhibitors of formula (X) in significantly high yield and purity.  
WO/2018/163194A1
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.  
WO/2018/155970A1
The present invention relates to a novel glucose derivative, and said novel compound is useful as an SGLT-2 inhibitor. In addition, the novel glucose derivative according to the present invention has a relatively higher melting point, lo...  
WO/2018/132073A1
There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a proce...  
WO/2018/089449A1
The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity...  
WO/2018/069490A1
A compound of formula (I) : (I) and its conjugates.  
WO/2018/032272A1
A novel method for preparing an important bioactive substance, oligomeric mannuronic diacid. The method uses oligomeric mannuronic acid as the starting material and obtains the target substance by means of steps of acid degradation and a...  
WO/2017/221211A1
The present invention provides for crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The prese...  
WO/2017/181102A1
Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiam...  
WO/2017/099496A1
The present invention relates to a novel solvate of dapagliflozin, an SGLT-2 inhibitor, and a method for preparing the same.  
WO/2017/098174A1
The present invention relates to a novel method for obtaining surfactant compositions made from alkyl-L-guluronamides or mixtures of L-guluronamides and D-mannuronamides, the compositions obtained by said method and the uses thereof.  
WO/2017/086443A1
The purpose of the present invention is to provide a 6'-sialyl lactose sodium salt (hereinafter referred to as 6SL) crystal that is easy to handle and has high preservation stability under normal and high temperature conditions and a met...  
WO/2017/085144A1
The invention relates to new compounds of formulae: Wherein: R 1 and R 2 can be independently H; a C 1 to C 6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R 1, R 2 together with the carbon C...  
WO/2017/060925A1
The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)- 2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetra hydro-2H-pyran- 3,4,5-trioland its amorphous form. The invention further discloses novelco- cry...  

Matches 1 - 50 out of 1,046